A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
NCT ID: NCT00073476
Last Updated: 2006-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
300 participants
INTERVENTIONAL
2003-09-30
2005-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
traxiprodil (CP-101,606)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Enrolled in study within 6 hours of onset of stroke symptoms
Willing to sign informed consent form
No significant disabilities prior to stroke
Exclusion Criteria
Premorbid modified rankin scale score of 2 or more
40 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
La Mesa, California, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Salisbury, North Carolina, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Dayton, Ohio, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Tartu, , Estonia
Pfizer Investigational Site
Bad Neustadt an der Saale, , Germany
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Lübeck, , Germany
Pfizer Investigational Site
Budapest, , Hungary
Pfizer Investigational Site
Győr, , Hungary
Pfizer Investigational Site
Pavia, , Italy
Pfizer Investigational Site
Perugia, , Italy
Pfizer Investigational Site
Coimbra, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Singapore, , Singapore
Pfizer Investigational Site
Santiago de Compostela, Galicia, Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1611005
Identifier Type: -
Identifier Source: org_study_id